SOLVENTUM CORP (SOLV)
Sector: Health Care
2026 Annual Meeting Analysis
SOLVENTUM CORP · Meeting: May 15, 2026
Directors FOR
4
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Director joined in 2024 (within 24 months of the 2026 meeting), so he is exempt from the TSR underperformance trigger under policy; no overboarding, attendance, or qualification concerns identified.
Director joined in 2024 (within 24 months of the 2026 meeting), so she is exempt from the TSR underperformance trigger; she holds two other public company board seats, which is within the four-board limit for non-CEO directors; no other concerns identified.
Director joined in 2024 (within 24 months of the 2026 meeting), so she is exempt from the TSR underperformance trigger; she holds two other public company board seats, within policy limits; she is an audit committee financial expert with strong relevant qualifications.
Director joined in 2024 (within 24 months of the 2026 meeting), so he is exempt from the TSR underperformance trigger; he holds two other public company board seats (RTX Corporation and U.S. Physical Therapy), within the four-board limit; no other concerns identified.
All four Class II director nominees joined the board in 2024, which is within the 24-month new-director exemption window under the voting policy. None of the nominees exceed the overboarding limits, all attended at least 75% of meetings, and the board has published a skills matrix. No policy triggers fire for any nominee.
Say on Pay
✓ FORCEO
Bryan C. Hanson
Total Comp
$20,139,981
Prior Support
~85%%
The prior year say-on-pay vote received approximately 85% support, well above the 70% threshold that would require visible remediation. The CEO's total reported compensation of approximately $20.1 million reflects a pay mix where 92% is variable and at-risk, comfortably exceeding the policy's 50-60% variable pay minimum. The company's annual incentive plan is tied to pre-set, measurable financial metrics (Constant Currency Revenue, Adjusted Operating Income, and Free Cash Flow), and long-term performance stock awards include a relative total shareholder return component benchmarked against the S&P 500 Healthcare Index, which directly links executive outcomes to shareholder outcomes. A robust clawback policy covering both restatement and misconduct scenarios is in place, and the company engaged with shareholders representing over 56% of outstanding shares in 2025 and made responsive changes to the program.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP (PwC)
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
The fee table excerpt in the filing does not provide specific dollar amounts for audit fees versus non-audit fees in a format that allows precise calculation of the non-audit fee ratio, so the fee-ratio trigger cannot be confirmed; per policy, when data is unavailable the trigger does not fire. PwC's tenure is not explicitly disclosed in the filing, so the tenure trigger does not apply. Solventum is a large-cap company (market cap ~$10.9B) and PwC is a Big 4 firm, satisfying the auditor adequacy standard. No material restatements are disclosed. The audit committee is composed entirely of independent directors, including two designated financial experts.
Overall Assessment
Solventum's 2026 annual meeting presents three standard proposals: election of four Class II directors (all newly appointed in 2024 and therefore exempt from the TSR underperformance trigger), ratification of PwC as auditor, and an advisory vote on executive compensation. All three proposals receive a FOR determination — the director slate is clean, the auditor is appropriate for the company's size, and the pay program is heavily performance-based with strong prior shareholder support.